SOLICITATION NOTICE
65 -- ADP-Glo Kinase Assay
- Notice Date
- 7/15/2010
- Notice Type
- Presolicitation
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-PB-(HG)-2010-197-DLM
- Archive Date
- 8/12/2010
- Point of Contact
- Dorothy Maxwell, Phone: 301-435-0352
- E-Mail Address
-
maxwelld@mail.nih.gov
(maxwelld@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), NIH Chemical Genomics Center (NCGC) intends to negotiate and award a purchase order on a noncompetitive sole source basis to Promega Corporation 2800 Woods Hollow Road, Madison, Wisconsin 53711-5399 to procure ADP-Glo Kinase Assay Kits. The National Institute of Health (NIH) is the nation’s medical research agency and the primary Federal agency conducting and supporting making medical discoveries that improve people’s health and save lives. The NIH Chemical Genomics Center regularly screens its small molecule library collections against enzyme targets with known implications for disease. As such, there is a clear need for kits or reagents which allow the sensitive and robust detection of enzyme activity in the presence of such small molecules. Promega’s ADP-Glo kit has been used and validated by the NCGC for several different assays, and remains the most sensitive and useful method of detection for such screening applications. One such project, related to the elucidation of inhibitors of the T. brucei isoform of phosphofructokinase, has been approved for screening, and the NCGC is in need of screening-quantity amounts of ADP-Glo, the validated and approved method of detection for this particular assay. Having this reagent is essential to this and several other ongoing projects at NCGC, and is crucial to our ability to continue and maintain fruitful collaborations with the many institutions with whom we work so closely. Description: 1. ADP-Glo Kinase Assay, Catalog Number V9103, Quantity: 15 Each. The sole source determination is based on the fact NIH Chemical Genomics Center has established a screening environment in which assays relevant to any number of diseases can be validated and screened against the institute’s in-house repository of +300,000 small molecules for activity. We have validated several assays that specifically use Promega’s ADP-Glo kits to measure the activity of enzymes, allowing us to screen for compounds with potential as lead drugs against a variety of rare and neglected disorders, such as African Sleeping Sickness and Chagas’ disease. Several vendors offer kits to measure ADP levels, which we have tested in lab, but only Promega’s ADP-Glo kit provides the luminescent readout and high level of sensitivity we need for our high-throughput screening applications. In addition, this particular kit is comprised of a proprietary collection of enzymes and buffers specifically optimized for such applications, and thus is not obtainable through any other vendors or means. Only one responsible source and no other supplies or services will satisfy agency requirements. The delivery point is the National Institutes of Health (NIH), National Human Genome Research Institute, NHGRI), 9800 Medical Center Drive, Building B, Room 1022, Rockville, Maryland 20850. Industry Classification (NAICS) Code is 325414, Biological Product (except Diagnostic) Manufacturing with business size standard of 500 employees. The acquisition is being conducted under FAR Part 13, simplified acquisition procedures, therefore the requirements of FAR Part 6 B Competitive Requirements are not applicable (FAR Part 6.001).and the resultant purchase order will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-44 (July 8, 2010). This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis, by July 28, 2010, 7:30 a.m. Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement. Inquires to this announcement, referencing synopsis number NHLBI-PB-(HG)-2010-197-DLM, may be submitted to the National Heart, Lung and Blood Institute, Office of Acquisition, Procurement Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to maxwelld@mail.nih.gov. Faxes will not be accepted. Responses will only be accepted if dated and signed by an authorized company representative.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-PB-(HG)-2010-197-DLM/listing.html)
- Place of Performance
- Address: NIH, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02206917-W 20100717/100715235125-3f1e3c301bb0b66c58bac25490e96370 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |